Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717
Recruiting
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.
Gender:
ALL
Ages:
Between 40 years and 100 years
Trial Updated:
08/13/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/13/2025
Locations: Road Runner Research Ltd, San Antonio, Texas
Conditions: Chronic Migraine in Children
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: Dell Children's Medical Center, Austin, Texas
Conditions: Acute Treatment of Migraine
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Seton Medical Center, Austin, Texas
Conditions: Peripheral Vascular Diseases
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: Dell Children's Medical Center, Austin, Texas
Conditions: Pediatric Migraine
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT04570423
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
08/13/2025
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors, Lymphoma
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
NCT04199026
Recruiting
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delive... Read More
Gender:
ALL
Ages:
10 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Register for Updates
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME
NCT04108156
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Retina Research Institute of Texas, Abilene, Texas
Conditions: Diabetic Macular Edema
Register for Updates
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
NCT04098744
Recruiting
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Gender:
FEMALE
Ages:
Between 25 years and 100 years
Trial Updated:
08/13/2025
Locations: The Harris Health System (L.B.J Hospital), Houston, Texas
Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Register for Updates
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04054167
Recruiting
This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Ultra low dose radiation is generally associated with a lower risk of side effects which may allow patients to be able to receive low-dose radiation therapy more often than high-dose radiation therap... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Register for Updates
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT03968406
Recruiting
This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Vaginal Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Malignant Female Reproductive System Neoplasm
Register for Updates